Ypsomed

What they make

3 inputs Ypsomed supplies

Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.

Where they make it

1 facility

Intelligence

What's known

Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.

• Did you know2024

  Ypsomed is publicly framed as a GLP-1 / weight-loss play — the autoinjector maker that signed a long-term YpsoMate supply deal with Novo Nordisk. But the same company is simultaneously one of the world's significant insulin-delivery-device makers: its mylife YpsoPump is a durable insulin pump, and its mylife CamAPS FX hybrid closed-loop algorithm (paired with Dexcom CGM) is an automated insulin delivery system competing head-to-head with Insulet's Omnipod, Tandem and Medtronic. The result is a single Solothurn-based device house sitting under TWO distinct essential-medicine supply chains in the radar at once — GLP-1 drugs (via the injection pen/autoinjector) and insulin (via pumps, pens and infusion sets). A regulatory action, fire, or capacity reallocation at Ypsomed would ripple into both the obesity-drug rollout and diabetes care, even though almost no one outside the device industry connects the two through this company.

  Ypsomed Holding AG ↗

• Concentration2024

  The binding constraint in the 2022-2024 GLP-1 shortage (Ozempic, Wegovy, Mounjaro) was not the active peptide — it was device fill-finish and autoinjector assembly capacity. That capacity, for pharma companies that do not build their own devices, is concentrated in two Swiss-based independent CDMOs: Ypsomed (Solothurn) and SHL Medical (Zug). Both are in Switzerland, both supply multiple competing pharma customers, and a qualified autoinjector platform cannot be re-sourced in under ~2-3 years because of tooling, sterile-assembly validation and device-change regulatory filings. The world's ability to physically deliver injectable obesity and diabetes drugs runs through a short list of Swiss device factories — a concentration that mirrors the drug-substance concentration but is far less visible.

  Ypsomed Holding AG ↗

• Origin2024

  Ypsomed exists because of insulin, not obesity drugs. The company traces directly to Disetronic, founded in 1984 by Willy Michel — one of the pioneers of the wearable insulin pump. In 2003 Disetronic sold its insulin-pump business to Roche for roughly CHF 1.3 billion, and Michel retained the injection-systems arm (pen injectors and self-injection devices). That retained business was reorganized as Ypsomed Holding AG and listed on the SIX Swiss Exchange in 2004. So the Swiss company now famous for building the autoinjectors behind the GLP-1 / weight-loss boom is, at its root, a diabetes-device house: it spent four decades learning to put a precise subcutaneous dose into a patient's hands, first for insulin and only recently for semaglutide-class drugs.

  Ypsomed Holding AG ↗

• Capacity2024

  To meet GLP-1 autoinjector demand, Ypsomed has announced capacity investments exceeding CHF 400 million, including a new production site in Schwerin, Germany and expansion of its Solothurn, Switzerland operations, targeting annual output scaling toward the order of one billion injection devices (autoinjectors and pens) by the end of the decade. The company carved out and sold its diabetes-care distribution unit (~$512 million) to concentrate capital on this delivery-systems build-out. The scale of the capex is itself a signal of how device-side — not API-side — the GLP-1 supply constraint is. [verify: CHF400M+ capex, Schwerin+Solothurn, diabetes-unit sale (~CHF420M) confirmed]

  Ypsomed Holding AG ↗